Enzolytics Inc. (OTCMKTS: ENZC) Advancing its ITC-1 Anti-HIV Therapy to Clinical Trials under EMA Across Europe

Enzolytics Inc. (OTCMKTS: ENZC) has finalized plans to advance the previously tested ITV-1 anti-HIV treatment to clinical studies and supply across Europe. Completing the steps will establish the anti-HIV therapy as a potential revenue source, a significant milestone for Enzolytics’ profitability and human health. 

Anti-HIV therapy progressing to clinical studies under EMA

The anti-HIV therapy had progressed toward Bulgarian Drug Agency certification, but the process was halted before completion. But, in the process, there were encouraging clinical study results documented that now give Enzolytics total confidence that the expected clinical studies under EMA will be successful. 

The company’s CSO Harry Zhabilov said, “We are excited about the progress we have made with the assistance of our partners at IMBL. Engaging Danhson Ltd., Clinical Design and PharmaLex is an integral step toward our success in the EMA permitting process. As this is the second time ITV-1 has gone through clinical trials and the first trials were successful, our confidence is at an all-time high regarding permitting and with the reciprocal treaty between the EMA and FDA, we believe that the “redo” on clinical trials will be a blessing in disguise in the long run.”

Sharabura appointed RustioMed President 

Enzolytics has appointed Steve Sharbura as the president of its Atlanta-based wholly-owned subsidiary RobustoMed Inc. RobustoMed is expected to start a new business model focusing on cultivating international collaboration openings for medical stage products and drug companies. Sharabura’s focus will be on partnership and revenue expansion in major markets globally that include specific initiatives in Coats Rica, Brazil, and emerging markets. 

Charles Cotropia, Enzolytics CEO, said, “We are pleased with the addition of Steve Sharabura to our team and look forward the benefits to be derived from the implementation of the new business model for RobustoMed. We look forward to significant growth in this new business segment.”